RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
14,50 $
arrow_downward
-1,83%(-0,27) 1D
14,49 $
arrow_downward
-0,07% (-0,010)bedtimeAfter hours
Closed: 25 қыр., 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
14,87 $
High
14,94 $
Low
14,15 $
Mkt. cap
1,43 млрд
Avg. vol.
5,21 млн
Volume
4,31 млн
52-wk high
39,89 $
52-wk low
12,73 $
EPS
-5,84 $
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 мың
Open
14,87 $
High
14,94 $
Low
14,15 $
Mkt. cap
1,43 млрд
Avg. vol.
5,21 млн
Volume
4,31 млн
52-wk high
39,89 $
52-wk low
12,73 $
EPS
-5,84 $
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 мың
News stories
From web sources and news partners
MarketBeat
·
6 сағат бұрын
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
Investing.com
·
1 күн бұрын
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval
The Business Journals
·
3 күн бұрын
Treatment invented at Nationwide Children’s for deadly disease gets FDA approval
Reuters
·
1 апта бұрын
Ultragenyx sets $3.95 million price for rare disease gene therapy
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 мың
Founded2010
HeadquartersNovato, Калифорния, Америка Құрама Штаттары
Sector-
Websiteultragenyx.com